4D Molecular Therapeutics Inc
FDMT
Company Profile
Business description
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Contact
5858 Horton Street
Suite 455
EmeryvilleCA94608
USAT: +1 510 505-2680
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
196
Stocks News & Analysis
stocks
ASX utility share downgraded as electricity prices fall
Falling electricity prices weigh on earnings outlook for utility provider.
stocks
Chart of the Week: AI market leader is now surprisingly cheap
This AI beneficiary may still be one of the market’s most compelling bargains.
stocks
Weekly earnings wrap: Rio Tinto leads the way
A closer look at the key earnings results from the first week of August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,452.00 | 42.10 | 0.45% |
| CAC 40 | 8,736.07 | 66.78 | 0.77% |
| DAX 40 | 26,196.40 | 70.10 | 0.27% |
| Dow JONES (US) | 54,313.22 | 35.90 | -0.07% |
| FTSE 100 | 10,873.77 | 14.53 | -0.13% |
| HKSE | 25,530.28 | 385.54 | -1.49% |
| NASDAQ | 26,441.01 | 77.57 | 0.29% |
| Nikkei 225 | 65,683.26 | 617.18 | -0.93% |
| NZX 50 Index | 13,958.06 | 39.12 | -0.28% |
| S&P 500 | 7,738.96 | 15.41 | 0.20% |
| S&P/ASX 200 | 9,271.60 | 41.80 | 0.45% |
| SSE Composite Index | 3,900.35 | 21.92 | 0.57% |